Concepts (60)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Coumarins | 13 | 2024 | 38 | 5.460 |
Why?
|
| Antineoplastic Agents | 7 | 2018 | 803 | 1.420 |
Why?
|
| S Phase | 2 | 2018 | 37 | 1.290 |
Why?
|
| Lung Neoplasms | 5 | 2023 | 358 | 1.170 |
Why?
|
| Monoamine Oxidase Inhibitors | 2 | 2024 | 25 | 0.980 |
Why?
|
| Cell Death | 3 | 2023 | 267 | 0.960 |
Why?
|
| Reactive Oxygen Species | 4 | 2023 | 461 | 0.950 |
Why?
|
| Cell Line, Tumor | 13 | 2024 | 2231 | 0.910 |
Why?
|
| Membrane Potential, Mitochondrial | 3 | 2018 | 84 | 0.870 |
Why?
|
| Cell Proliferation | 3 | 2017 | 1198 | 0.730 |
Why?
|
| Apoptosis | 2 | 2017 | 1398 | 0.600 |
Why?
|
| Breast Neoplasms | 5 | 2024 | 1502 | 0.550 |
Why?
|
| Cell Cycle | 5 | 2015 | 326 | 0.500 |
Why?
|
| Ethylenediamines | 1 | 2014 | 7 | 0.480 |
Why?
|
| Humans | 17 | 2024 | 37093 | 0.370 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2010 | 33 | 0.370 |
Why?
|
| Selective Estrogen Receptor Modulators | 2 | 2008 | 32 | 0.360 |
Why?
|
| Structure-Activity Relationship | 3 | 2020 | 409 | 0.320 |
Why?
|
| Prostatic Neoplasms | 1 | 2017 | 935 | 0.320 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2014 | 113 | 0.310 |
Why?
|
| Cell Survival | 3 | 2018 | 864 | 0.300 |
Why?
|
| Matrix Metalloproteinases | 2 | 2018 | 48 | 0.290 |
Why?
|
| Thiophenes | 1 | 2007 | 31 | 0.280 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2020 | 83 | 0.280 |
Why?
|
| Stilbenes | 1 | 2007 | 44 | 0.280 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2015 | 1039 | 0.270 |
Why?
|
| Drug Design | 1 | 2007 | 162 | 0.260 |
Why?
|
| Cell Line | 2 | 2023 | 1354 | 0.240 |
Why?
|
| Monoamine Oxidase | 1 | 2024 | 34 | 0.240 |
Why?
|
| Neoplasms | 1 | 2011 | 1103 | 0.190 |
Why?
|
| Crystallography, X-Ray | 1 | 2020 | 265 | 0.180 |
Why?
|
| Estrogens | 2 | 2013 | 202 | 0.170 |
Why?
|
| Molecular Structure | 1 | 2020 | 492 | 0.160 |
Why?
|
| Tamoxifen | 2 | 2010 | 65 | 0.160 |
Why?
|
| Free Radical Scavengers | 1 | 2018 | 66 | 0.160 |
Why?
|
| Acetylcysteine | 1 | 2018 | 62 | 0.160 |
Why?
|
| Receptors, Estrogen | 2 | 2010 | 156 | 0.150 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 2 | 2014 | 132 | 0.140 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 502 | 0.140 |
Why?
|
| Antioxidants | 1 | 2018 | 416 | 0.130 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2015 | 112 | 0.120 |
Why?
|
| Mitochondria | 1 | 2017 | 487 | 0.120 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2012 | 77 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 152 | 0.100 |
Why?
|
| Male | 2 | 2023 | 20025 | 0.100 |
Why?
|
| Down-Regulation | 1 | 2012 | 435 | 0.090 |
Why?
|
| Up-Regulation | 1 | 2012 | 513 | 0.090 |
Why?
|
| Flow Cytometry | 1 | 2010 | 399 | 0.080 |
Why?
|
| Liver Neoplasms | 1 | 2011 | 190 | 0.080 |
Why?
|
| Liver | 1 | 2011 | 479 | 0.080 |
Why?
|
| Lung | 1 | 2010 | 446 | 0.080 |
Why?
|
| Toremifene | 1 | 2007 | 4 | 0.070 |
Why?
|
| Models, Molecular | 1 | 2010 | 808 | 0.070 |
Why?
|
| Cells, Cultured | 1 | 2010 | 1518 | 0.070 |
Why?
|
| Estrogen Receptor alpha | 1 | 2007 | 111 | 0.070 |
Why?
|
| Female | 3 | 2018 | 20969 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 433 | 0.070 |
Why?
|
| Rats | 1 | 2011 | 3483 | 0.060 |
Why?
|
| Animals | 1 | 2011 | 15081 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2013 | 289 | 0.030 |
Why?
|